This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Restaurant Stocks to Gain Big With the Vaccine Rollout
by Zacks Equity Research
Restaurant industry is likely to benefit from the vaccine rollout. Following the vaccine rollout, dine-in option should become safe and traffic is likely to increase.
Pfizer/BioNTech to Sell More COVID-19 Vaccine Doses to U.S.
by Zacks Equity Research
Pfizer (PFE)/BioNTech(BNTX) won a deal for 100 million more doses of its COVID-19 vaccine in the United States.
Amgen/AstraZeneca's Asthma Drug Misses Phase III Study Goal
by Zacks Equity Research
Amgen (AMGN) and AstraZeneca (AZN) plan to file regulatory applications for tezepelumab next year.
How Effective Will Vaccines be Against New Coronavirus Strain?
by Indrajit Bandyopadhyay
Pfizer (PFE) and Moderna (MRNA), the companies whose coronavirus vaccines have been approved for emergency use, are evaluating their vaccines against the fast-spreading new strain of coronavirus found in the United Kingdom.
4 Restaurant Stocks to Play a Likely Turnaround in 2021
by Mrithunjoy Kaushik
Although the restaurant industry is grappling with the coronavirus outbreak, restaurant stocks like JACK, RUTH, FAT and STKS have impressive 2021 earnings growth projections.
Pfizer/BioNTech COVID-19 Vaccine Gets Authorization in Europe
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate is the first COVID-19 vaccine to be granted conditional authorization in Europe.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Astrazeneca (AZN) closed at $49.63, marking a -1.16% move from the previous day.
4 Healthcare Stocks to Take Care of in 2021 to Boost Portfolio
by Srijita Guha
Based on strong fundamentals, here we talk about four healthcare stocks to keep in your watchlist for 2021.
Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing
by Zacks Equity Research
An FDA panel recommends granting approval for emergency use to Moderna's (MRNA) coronavirus vaccine candidate.
Pharma Stock Roundup: FDA Emergency Nod to PFE/BNTX COVID-19 Vaccine, AZN to Buy ALXN
by Kinjel Shah
FDA grants approval for emergency use of Pfizer's (PFE) COVID-19 vaccine. AstraZeneca (AZN) offers to buy Alexion.
TIPS ETFs to Buy for 2021 on Inflation Trade
by Sweta Killa
The COVID-19 vaccines and their availability have raised the prospect of inflation as we move ahead into the next year.
Moderna Vaccine: The Power of mRNA Technology
by Kevin Cook
Warp speed was just the ticket to launch top COVID-19 vaccines -- and a revolution in medicine
Top Analyst Reports for Mastercard, Eli Lilly & Citigroup
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Eli Lilly (LLY) and Citigroup (C).
Biotech Stock Roundup: ALXN Up on Acquisition News, PFE-BNTX Get EUA for Vaccine & More
by Zacks Equity Research
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) and Alexion's (ALXN) acquisition grab headlines this week.
Moderna (MRNA) Vaccine May Get Emergency Approval This Week
by Zacks Equity Research
An advisory committee meeting is scheduled on Dec 17 to discuss emergency use authorization for Moderna's (MRNA) COVID-19 vaccine candidate, mRNA-1273.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
by Sweta Killa
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
AstraZeneca's (AZN) Triple Combo COPD Therapy Gets EU Nod
by Zacks Equity Research
AstraZeneca (AZN) gets European approval for triple combination therapy, Trixeo Aerosphere for COPD. CHMP recommends approval of trastuzumab deruxtecan for breast cancer.
Company News for Dec 15, 2020
by Zacks Equity Research
Companies In The News Are: BA, ALXN, AZN, CVAC, GOOGL.
Vaccines Get to America, but Congressional Relief Lacking
by Mark Vickery
Market indexes began the day solidly in the green, but a bit of bearish trepidation crept in during the day, helping the Dow and S&P 500 finish down.
Alexion (ALXN) to Be Acquired by AstraZeneca for $39 Billion
by Zacks Equity Research
Alexion (ALXN) is set to be acquired by AstraZeneca for $39 billion or $175 per share. The acquisition is expected to close in the third quarter of 2021.
Wall Street Surges on COVID-19 Vaccine Approval
by Zacks Equity Research
Wall Street Surges on COVID-19 Vaccine Approval.
6 Consumer Discretionary ETFs Riding on Holiday Fervor
by Sweta Killa
U.S. consumers grew more confident in the economy in early December on the prospects of a vaccine, which has bolstered the holiday mood.
Historic Day for Pfizer (PFE), Covid-19 Vaccine
by Mark Vickery
With more than 180K daily reported cases as of yesterday, with more than 109K hospitalizations and nearly 1500 deaths on Sunday alone, this vaccine availability is not just historic, it's momentous.
Stocks Decline modestly, but Vaccine Optimism Promises a New Rally
by David Borun
A massive rollout of vaccine distribution is the best hope yet for a "return to normal."
ETFs to Win & Lose From the Surge in Oil Price
by Sweta Killa
Oil price has been on a surge in recent months buoyed by solid development on the COVID-19 vaccine front.